Systolic heart failure: a prothrombotic state.
Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic state in heart failure. This article focuses on this prothrombotic state and discusses the risk of thromboembolic events, pathophysiological mechanisms, and the potential role of anticoagulant treatment.
de Peuter
Olav R
OR
Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, The Netherlands. O.R.dePeuter@amc.uva.nl
Kok
Wouter E M
WE
Torp-Pedersen
Christian
C
Büller
Harry R
HR
Kamphuisen
Pieter W
PW
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D054143:Heart Failure, Systolic / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D011655:Pulmonary Embolism / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects; D013923:Thromboembolism / Q000209:etiology; D014859:Warfarin / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin